
💙 Are You Being Heard in Your Kidney Cancer Care? Past surveys show a record 55% of patients now feel definitely involved in their treatment decisions, yet huge gaps remain globally from 75% in the US to 30% in the Republic of Korea.

I am a physician specializing in the treatment of genitourinary cancers. I am passionate for improving cancer therapy through research.

💙 Are You Being Heard in Your Kidney Cancer Care? Past surveys show a record 55% of patients now feel definitely involved in their treatment decisions, yet huge gaps remain globally from 75% in the US to 30% in the Republic of Korea.

So excited to be back in Nashville for UromigosLive 2026 @brian_rini @tompowles1 @katy_beckermann @TiansterZhang @montypal @PGrivasMDPhD @neerajaiims @Dr_Aggen @shilpaonc @DrScottHaake @AmandaNizamMD @Uromigos


YES!! So proud to work with a leader of symptom management @lynnhenrymd on this trial when both of us were @huntsmancancer Exercising makes a huge difference in the lives of prostate cancer patients.
🏃♂️ Can exercise meaningfully reduce fatigue in advanced prostate cancer? The answer appears to be yes. academic.oup.com/oncolo/adva… A prospective trial of a personalized exercise program in patients with advanced prostate cancer A prospective trial evaluated a 12-week structured exercise program for patients with advanced prostate cancer receiving androgen deprivation therapy and experiencing fatigue. ➡️Among 72 evaluable patients, fatigue improved by 5.1 PROMIS T-score points, representing a clinically significant reduction. ➡️ Among 76 patients completing fitness assessments, peak aerobic capacity improved by 3.1 ml/kg/min. Supervised weekly exercise combined with home aerobic and resistance training therefore significantly improved fatigue and physical fitness. #ProstateCancer @maughanonc, @ggebraelmd, @neerajaiims, @umangtalking @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

🏃♂️ Can exercise meaningfully reduce fatigue in advanced prostate cancer? The answer appears to be yes. academic.oup.com/oncolo/adva… A prospective trial of a personalized exercise program in patients with advanced prostate cancer A prospective trial evaluated a 12-week structured exercise program for patients with advanced prostate cancer receiving androgen deprivation therapy and experiencing fatigue. ➡️Among 72 evaluable patients, fatigue improved by 5.1 PROMIS T-score points, representing a clinically significant reduction. ➡️ Among 76 patients completing fitness assessments, peak aerobic capacity improved by 3.1 ml/kg/min. Supervised weekly exercise combined with home aerobic and resistance training therefore significantly improved fatigue and physical fitness. #ProstateCancer @maughanonc, @ggebraelmd, @neerajaiims, @umangtalking @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Standing room only at the OneOncology Annual Conference state of the union this morning. @OneOncology I'm proud to be part of a physician-led organization that keeps growing. New this year is a urology-only track, which means more GU-focused partners in the room with us. In bladder, kidney and prostate cancer, the patients who do best usually have the entire care team urologist, rad onc, and a medical oncologist working closely together. #CommunityOncology #GUonc #Urology

Agreed - good luck Petros
@PGrivasMDPhD is a brilliant clinician, a humble leader and a wonderful human being!

My wife is the type of thoughtful physician I aspire to be She’s working urgent care tonight and seeing kids who are too sick to go trick-or-treating so she brought them toys to take home in the hopes they don’t feel too left out Talk about putting care in healthcare ❤️

I have know Monty for a decade now. He is a wonderful colleague, oncologist and now friend. He always has time for colleagues and in particular trainees. His commitment to them and his patients shines through. I strongly recommend Monty for the ASCO board. @OpenMedKate @StephenVLiu @brian_rini @kor_shah @OpenMedInsights @OpenMedicineHQ @OncBrothers @StephenVLiu @AlanBryce9 @OncoThor @TylerSbrt
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!

An effective Board of Directors can shape an organization. @montypal has the vision and leadership to guide and grow ASCO nationally and internationally.
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!

So many incredible folks on this list - many of whom are treasured friends. To @shilpaonc & @PBarataMD, now running phase III trials and making sea changes in how we treat #genitourinary cancers, congratulations! To @curijoey, the 2027-2028 @myESMO President, congratulations! To @GregoryAVidal, who I have exchanged ideas over Lou Malnati's pizza with at many an @ASCO, congratulations! And to @NazliDizman, what more can I say! Achieving the #FASCO status within your first 3 months as faculty at @DanaFarber isan incredible feat & a sign of what's to come! Congrats to everyone on this list (@Joshua_Reuss, @ryangentzler, @VjChaudharyMD & everyone else!) & thank you for your commitment to @ASCO!
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: bit.ly/4BvJVrG

@ASCO elections are open now until Dec 2nd! This year proud to support friends @montypal @PGrivasMDPhD @wandering_gu Todd Morgan @AshleySumrallMD -- and @teekayowo for President Elect! Vote for ASCO asco.org/election @OncoAlert @WomeninOnc

Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU
Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ

SWOG S2200: Cabozantinib with or Without Atezolizumab in Metastatic Papillary RCC. Presented by @maughanonc @huntsmancancer. #ESMO26 written coverage by @rksayyid @UAUrology > bit.ly/4yLiKH1 #KidneyCancer #RCC #Immunotherapy @myESMO @SWOG

VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy alone (0.51 and 0.58 respectively). pCR 40-45% with ctDNA clearance rates of 60%. High rates of adjuvant IO therapy uptake and low rates of neuropathy suggest potential advantages of this approach which focuses the ADC in the neoadjuvant phase. It’s likely to be attractive for patients.

Leaving Madrid w so many good moments #ESMO26 @myESMO - brain exploding w data & new trials for our patients, feet sore, heart full after connecting w/ old & new friends across the world. Was an incredibly hard wk w loss of Rachna — we continue the hard & good work. @OncoAlert